Formulary Drug Review: Belumosudil

2021 ◽  
pp. 001857872110613
Author(s):  
Terri L. Levien ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Review ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Formulary Drug Review: Edaravone

2017 ◽  
Vol 52 (11) ◽  
pp. 732-736 ◽  
Author(s):  
Zaynah K. Ali ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Review ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Formulary Drug Review: Ocrelizumab

2017 ◽  
Vol 52 (9) ◽  
pp. 599-606
Author(s):  
Zaynah K. Ali ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Review ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Formulary Drug Review: Sufentanil Sublingual

2019 ◽  
Vol 54 (4) ◽  
pp. 222-228 ◽  
Author(s):  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Review ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Formulary Drug Review: Betrixaban

2017 ◽  
Vol 53 (1) ◽  
pp. 29-37 ◽  
Author(s):  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Review ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Fostemsavir

2021 ◽  
pp. 001857872098543
Author(s):  
Brittany M. Craft ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Lixisenatide

2017 ◽  
Vol 52 (1) ◽  
pp. 65-80
Author(s):  
Danial E. Baker ◽  
Terri L. Levien
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The January 2017 monograph topics are bezlotoxumab, buprenorphine buccal, defazacort, dupilumab, and olaratumab. The DUE is on buprenorphine buccal.

scholarly journals Omadacycline

2019 ◽  
Vol 54 (2) ◽  
pp. 80-87 ◽  
Author(s):  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

scholarly journals Daclizumab

2016 ◽  
Vol 51 (11) ◽  
pp. 928-939 ◽  
Author(s):  
Anne P. Kim ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433. The December 2016 monograph topics are ozenoxacin cream, ocrelizumab, naldemedine, eteplirsen, and abaloparatide. The Safety MUE is on buprenorphine buccal.

scholarly journals Angiotensin II

2018 ◽  
Vol 53 (4) ◽  
pp. 230-233
Author(s):  
Danial E. Baker ◽  
Terri L. Levien
Keyword(s):  
Angiotensin Ii ◽  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Vericiguat

2021 ◽  
pp. 001857872110163
Author(s):  
Luong Nguyen ◽  
Danial E. Baker
Keyword(s):  
Customer Service ◽  
Drug Utilization ◽  
Hospital Pharmacy ◽  
Late Phase ◽  
Medication Use ◽  
Phase 3 ◽  
Target Drug ◽  
Service Contact ◽  
Drug Utilization Evaluation

Each month, subscribers to The Formulary Monograph Service receive 5 to 6 well-documented monographs on drugs that are newly released or are in late phase 3 trials. The monographs are targeted to Pharmacy & Therapeutics Committees. Subscribers also receive monthly 1-page summary monographs on agents that are useful for agendas and pharmacy/nursing in-services. A comprehensive target drug utilization evaluation/medication use evaluation (DUE/MUE) is also provided each month. With a subscription, the monographs are available online to subscribers. Monographs can be customized to meet the needs of a facility. Through the cooperation of The Formulary, Hospital Pharmacy publishes selected reviews in this column. For more information about The Formulary Monograph Service, contact Wolters Kluwer customer service at 866-397-3433.

Sign in / Sign up

Export Citation Format

Share Document